Noélia Che
YOU?
Author Swipe
View article: Synergistic Strategies for KMT2A-Rearranged Leukemias: Beyond Menin Inhibitor
Synergistic Strategies for KMT2A-Rearranged Leukemias: Beyond Menin Inhibitor Open
KMT2A-rearranged leukemias are a highly aggressive subset of acute leukemia, characterized by poor prognosis and frequent relapses despite intensive treatment. Menin inhibitors, which target the critical KMT2A–menin interaction driving leu…
View article: Enhanced depletion of MLL-fusion proteins in acute leukemia: potential for improved therapeutic outcomes
Enhanced depletion of MLL-fusion proteins in acute leukemia: potential for improved therapeutic outcomes Open
Rearrangements of the MLL ( KMT2A ) locus are associated with aggressive leukaemia of both myeloid and lymphoid lineages, that present profound therapeutic challenges in pediatric and adult patient populations. MLL -fusion genes resulting …
View article: Susceptibility of pediatric acute lymphoblastic leukemia to STAT3 inhibition depends on p53 induction
Susceptibility of pediatric acute lymphoblastic leukemia to STAT3 inhibition depends on p53 induction Open
Advances in the clinical management of pediatric B cell Acute Lymphoblastic Leukemia (B-ALL) have dramatically improved outcomes for this disease. However, relapsed and high-risk disease still contribute to significant numbers of treatment…
View article: Loss of tyrosine catabolic enzyme HPD promotes glutamine anaplerosis through mTOR signaling in liver cancer
Loss of tyrosine catabolic enzyme HPD promotes glutamine anaplerosis through mTOR signaling in liver cancer Open
(Cell Reports 36, 109617-1–109617-14.e1–e5; August 24, 2021) In the originally published version of this article, the lead contact was assigned unwittingly and wrongly to Dr. Man Tong. The correct lead contact for this article is Dr. Steph…
View article: Overriding Adaptive Resistance to Sorafenib Through Combination Therapy With Src Homology 2 Domain–Containing Phosphatase 2 Blockade in Hepatocellular Carcinoma
Overriding Adaptive Resistance to Sorafenib Through Combination Therapy With Src Homology 2 Domain–Containing Phosphatase 2 Blockade in Hepatocellular Carcinoma Open
Background and Aims The survival benefit of sorafenib for patients with hepatocellular carcinoma (HCC) is unsatisfactory due to the development of adaptive resistance. Increasing evidence has demonstrated that drug resistance can be acquir…